cagrilintide 5mg reconstitution Cagrilintide 5mg – Research Peptide

Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs

Complementary mechanism addressing both cause (pressure) and consequence (neural damage)

As the WL achieved with the novel obesity pharmacotherapies approaches that of bariatric surgery, we will need to assess whether long-term complications observed after bariatric surgery such as increased risk of osteoporosis, fractures, macro- and micronutrient deficiencies as well as self-harm behaviours will also be present with pharmacotherapy [112, 113]

Neuroinflammation 17 , 19 (2020)

10.1016/j.bbrc.2007.06.002

Neuroprotection: Beyond just fixing the structure, there's evidence that BPC 157 has neuroprotective qualities, potentially shielding the compressed nerves from further damage and promoting their recovery